Trimetazidine

Generic Name: Trimetazidine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₂N_₂O_₃

CAS Number: 5011-34-7

Unique Ingredient Identifier: N9A0A0R9S8

Background: Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.

Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems. The increased intracellular calcium decreases contractility. It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate ischemic injury. However, evidence for this mechanism is controversial.

Trimetazidine is not FDA approved. However, it has been approved in France since 1978.

Indication: Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.

Associated Conditions: Angina Pectoris, Chronic Stable Angina Pectoris, Tinnitus, Vertigo, Decreased visual acuity caused by Vascular Disorders

Associated Therapies: -

Clinical Trials

"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"

Phase 3

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Trimetazidine

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT06656442

Locations: 🇪🇬
Ain Shams University Hospital, Cairo, Egypt

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Phase 1

Recruiting

Conditions: Peripheral Neuropathy Due to Chemotherapy

Interventions: Drug: Placebo
Drug: Trimetazidine

First Posted Date: 2024-06-14

Last Posted Date: 2024-11-21

Lead Sponsor: Minia University

Target Recruit Count: 60

Registration Number: NCT06459193

Locations: 🇪🇬
Minia Oncology Center, Minya, Egypt

Benefits of Trimetazidine in MAFLD Pateints

Phase 2

Recruiting

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Drug: conventional treatment
Drug: Furosemide or other alternatives , Niaspan or other alternatives
Drug: Trimetazidine

First Posted Date: 2023-11-21

Last Posted Date: 2023-11-21

Lead Sponsor: October 6 University

Target Recruit Count: 60

Registration Number: NCT06140953

Locations: 🇪🇬
Maha Youssif Fekry, Giza, October 6, Egypt

The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

Phase 4

Completed

Conditions: Mitochondrial Pathology
Transthyretin Amyloid Cardiopathy

Interventions: Drug: Placebo
Drug: Trimetazidine

First Posted Date: 2022-12-01

Last Posted Date: 2024-04-25

Lead Sponsor: Steen Hvitfeldt Poulsen

Target Recruit Count: 24

Registration Number: NCT05633563

Locations: 🇩🇰
Aarhus University Hospital, Department of Cardiology, Aarhus N, Danmark, Denmark

Efficacy of Trimetazidine in Diabetic Patients

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 2
Diabetic Cardiomyopathies

Interventions: Drug: Placebo
Drug: Trimetazidine Dihydrochloride

First Posted Date: 2022-09-27

Last Posted Date: 2022-09-27

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT05556005

Locations: 🇪🇬
Ainshams university hospitals, Cairo, Egypt

The Effects of TMZ on Diabetic Nephropathy

Phase 2

Conditions: Diabetic Nephropathies

Interventions: Drug: Trimetazidine

First Posted Date: 2021-12-07

Last Posted Date: 2021-12-07

Lead Sponsor: Tongji Hospital

Target Recruit Count: 150

Registration Number: NCT05147194

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Phase 2

Conditions: Cardiotoxicity

Interventions: Drug: Trimetazidine

First Posted Date: 2021-06-25

Last Posted Date: 2021-06-25

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 80

Registration Number: NCT04939857

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Motor Neuron Disease
Amyotrophic Lateral Sclerosis

Interventions: Drug: Trimetazidine Dihydrochloride

First Posted Date: 2021-03-09

Last Posted Date: 2023-07-20

Lead Sponsor: The University of Queensland

Target Recruit Count: 21

Registration Number: NCT04788745

Locations: 🇬🇧
King's College London, London, United Kingdom
🇦🇺
Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia
🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands